CTT

Cancer Targeting Technology (CTT) is a clinical-stage biotechnology company based in South Korea that specializes in the development of targeted radiopharmaceuticals for oncology. The company's core expertise lies in its proprietary phosphoramidate-based platform, which enables the creation of ligands that bind irreversibly to Prostate-Specific Membrane Antigen (PSMA). Their lead diagnostic candidate, CTT1057, is an 18F-labeled PET imaging agent currently in Phase 2 clinical trials and has been licensed to Curium for global development. CTT is also advancing a therapeutic pipeline, including CTT1403, a Lutetium-177 labeled agent for the treatment of metastatic castration-resistant prostate cancer. The company's approach focuses on providing high-precision theranostic solutions to improve patient outcomes in prostate cancer.